RETATRUTIDE
- ≥99% purity by HPLC
- Janoshik COA with every lot
- Lot-traceable from synthesis
- EU-synthesised
Specifications
Third Party Lab Tested
Every lot is independently HPLC-tested by Janoshik Analytical, Europe's reference laboratory for peptide purity assessment. The COA shipped with your order is theirs, not ours.
Storage & Handling
Lyophilized peptides should be stored below 16°C, protected from light and moisture, for up to 24 months. Once reconstituted, refrigerate and use within 30 days for protocol consistency.
Reconstitution
Reconstitute with bacteriostatic water using the volumes below. Add solvent slowly along the inside wall of the vial. Swirl gently, never shake, until fully dissolved.
Lab-handling protocol BAC Water · 0.9% benzyl alcohol The reconstitution solvent referenced above. Add to order →The triple agonist
frontier.
Retatrutide adds glucagon-receptor activation on top of the GLP-1 / GIP profile. The third pathway recruits hepatic energy expenditure and lipolysis into the response, broadening the metabolic envelope beyond what dual agonists can produce.
It is the most active investigational compound in published metabolic research today. Receptor selectivity, pulse kinetics, and downstream effects all sit further from the GLP-1 baseline than any other commercially available analog.
| Compound | Retatrutide |
|---|---|
| Sequence length | 39 amino acids |
| Molecular mass | 4731.2 Da |
| Modeled half-life | ~6 days (modeled) |
| Mechanism / research class | GLP-1R / GIPR / GCGR agonist. |
| Lab handling solvent | 2mL bacteriostatic water for injection (BWI) |
| Resulting concentration | Yields 5mg per 1.0mL |
| Supply format | Retatrutide · 10MG lyophilized research vial |
| Storage, lyophilized | store below 16°C for up to 24 months |
| Storage, reconstituted | refrigerate and use within 30 days |
Synthesised.
Verified.
Documented.
Backed by research.
Measured in results.
Each tag opens the cited literature behind that effect. References are linked to PubMed.
Retatrutide is the first reported GLP-1 / GIP / glucagon triple agonist in published research. The added GCGR activation engages hepatic energy expenditure and lipolysis on top of the dual incretin profile, producing a steeper body-weight response than dual agonists in head-to-head reference trials.
Phase 2 trial reported −24.2% mean body-weight reduction at 48 weeks in the highest published study arm.
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. NEJM. 2023;389(6):514-526. PubMed ↗
The triple-agonist mechanism is particularly active on hepatic lipid handling. The Retatrutide MASLD substudy reported up to 86% relative liver-fat reduction at 48 weeks - the steepest reduction reported for any incretin analog to date.
- Sanyal AJ et al. Triple agonist retatrutide on MASLD in a phase 2a substudy. Nat Med. 2024;30:2037-2048. PubMed ↗
GCGR engagement adds hepatic energy-expenditure modulation to the response envelope. Research populations show improvements on HOMA-IR and broader insulin-sensitivity markers consistent with the triple-pathway profile.
- Sanyal AJ et al. Nat Med. 2024;30:2037-2048. PubMed ↗
Despite GCGR activation (which can theoretically raise hepatic glucose output), net glycemic effect in research populations remains strongly negative - A1C reductions of 1.7–2.0% reported in the phase 2 trial across the higher dose arms.
- Rosenstock J et al. Retatrutide in T2D. The Lancet. 2023;402(10401):529-544. PubMed ↗
Questions?
We got answers.
Show references
Used in published research.
4.9 / 5
Solid product, fast EU shipping
Ordered RETATRUTIDE for a research-protocol pilot. Arrived in 4 days temperature-controlled, vials sealed and properly lyophilized. Reconstituted cleanly in BWI with no haze. Will reorder.
